AI platform designs 'molecular missiles' to attack cancer cells

Researchers from DTU and Scripps Research Institute developed an AI platform that speeds up protein design for cancer treatment. Published in Science, the platform can create proteins to guide T cells against cancer cells in just 4-6 weeks.

Tests targeting the common cancer marker NY-ESO-1 resulted in minibinders that helped T cells kill cancer cells in lab settings. It also designed binders for metastatic melanoma, showing its potential for personalized immunotherapy.

A virtual safety check reduces the risk of harming healthy cells. Clinical trials could begin within five years, potentially transforming treatments like CAR-T cell therapy.